ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
November 05 2007 - 6:00AM
PR Newswire (US)
SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that Brian M. Culley, ADVENTRX's chief business
officer, is scheduled to present at the 13th Annual BIO-Europe
Partnering Conference on November 14th, 2007 at 11:30 a.m. Central
European Time (5:30 a.m. Eastern Time). The conference takes place
in Hamburg, Germany at the CCH Congress Center, November 12 - 14,
2007. According to BIO-Europe, the 13th annual BIO-Europe event is
the world's largest dedicated biotechnology partnering conference.
Almost two thousand global decision-makers from biotechnology,
pharma and finance annually attend BIO-Europe to identify new
business opportunities and develop strategic relationships.
BIO-Europe features the industry's most advanced web-based
partnering system, enabling delegates from all parts of the
biotechnology value-chain to quickly identify, engage and enter
into the strategic relationships that drive their business
successfully forward. About ADVENTRX Pharmaceuticals ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on commercializing proprietary product candidates
for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments
by addressing significant problems such as drug metabolism,
bioavailability, excessive toxicity and treatment resistance. More
information can be found on the Company's web site at
http://www.adventrx.com/. Forward Looking Statements ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they
materialize or do not prove to be accurate, could cause ADVENTRX's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the risk
that ADVENTRX will be unable to raise sufficient capital to fund
the projects necessary to meet its anticipated or stated goals and
milestones; the ability to timely enroll subjects in and the
results of ADVENTRX's current and anticipated clinical trials; the
potential for ADVENTRX's product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval; the
market potential for ADVENTRX's product candidates and ADVENTRX's
ability to compete in those markets; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024